The results demonstrate the ␣-helical secondary structure of the domain and suggest its orientation with respect to the other transmembrane domains. The C-terminal part of the helix appears to be largely buried within the receptor structure. On its surface, there is a patch of three residues, Val 113 , Leu 116 , and Ser 120 , which may form intramolecular contacts that help to stabilize the inactive ground state of the receptor. Mutagenic disruption of these increased agonist affinity and signaling efficacy. In two cases (L116A and S120A), this led to constitutive activation of the receptor. Parallel to the helix axis and spanning the whole transmembrane region, a distinct strip of residues on one face of transmembrane domain 3 forms intermolecular (acetylcholine-receptor, receptor-G protein) or intrareceptor bonds that contribute to the activated state. The binding of acetylcholine may destabilize the first set of contacts while favoring the formation of the second.
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forms the core of the seven-membered helical bundle that traverses the phospholipid bilayer (1, 2) . Spin labeling and cross-linking studies on Cys-substituted rhodopsin mutants have shown that a reorganization of the contacts between TMD 3 and surrounding transmembrane domains probably accompanies receptor activation (3) (4) (5) . Substituted cysteine accessibility mutagenesis of TMD 3 of the D 2 dopamine receptor has supported its ␣-helical character (6) .
TMD 3 of the M 1 muscarinic acetylcholine receptor (mAChR) is constrained at its N terminus by the conserved disulfidebonded residue Cys 98 (7, 8) . It carries the acetylcholine (ACh) binding side chain of Asp 105 (9, 10) and, near its C terminus, Arg 123 , which is completely conserved in the rhodopsin-like G protein-coupled receptors and is important in G protein binding and activation (11, 12) . In the M 1 mAChR, the highly conserved residues Asp 122 and Tyr 124 appear to make intramolecular contacts whose integrity is important for receptor expression (13) . Other residues within TMD 3 may also make inter-or intramolecular contacts, and these may be important determinants of receptor structure and activation.
Scanning mutagenesis can help to establish the secondary structure of receptor domains (6) and to locate and define functional epitopes within them (14) . Replacement of individual amino acids by alanine, which deletes the side chain beyond the ␤-carbon (in this study, Ala residues themselves were replaced by Gly), is normally well tolerated and allows the functions of individual side chains to be probed and analyzed (15) . We have applied this systematic approach to residues 100 -121 of TMD 3 of the M 1 mAChR.
The results show that different, topographically distinct, groups of amino acids are responsible for the selective stabilization of the ground and activated states of the receptor. We propose that ACh binding causes TMD 3 to switch from one set of contacts to the other. A preliminary account of some of these results has been given (16) . EXPERIMENTAL 
PROCEDURES
Experimental procedures were performed as described previously (10, 12, 13) .
Mutagenesis and Expression-Briefly, residues 100 -121 of the rat M 1 mAChR were individually mutated to Ala (or, if they were Ala in the parent sequence, to Gly), using a polymerase chain reaction method. After verification by dideoxy sequencing, mutant receptors were subcloned into the pCD expression vector and expressed transiently in COS-7 cells by electroporation using a Bio-Rad Gene Pulser at 180 V and 960 microfarads with 10 g of DNA/0.4-cm cuvette (4 ϫ 10 7 cells, 0.8 ml). Membrane preparations were made after 72 h as described previously (13) .
Binding and Functional Assays-Binding of (Ϫ)-N- ]QNB) to membrane preparations was measured at 30°C in a buffer containing 20 mM Na-HEPES, 100 mM NaCl and 1 mM MgCl 2 using an incubation time of 60 min to 3 h, as described previously (10) . The binding of ACh and other unlabeled ligands was measured by inhibition of the binding of the tritiated antagonist. For the study of guanine nucleotide shifts, MgCl 2 was replaced by 2 mM MnCl 2 (12) .
Phosphoinositide (PI) turnover was assayed as described previously (12, 13) . Briefly, transfected COS-7 cells were prelabeled with [ 3 H] inositol for 48 h, followed by washing and preincubation with Krebs bicarbonate solution containing 10 mM LiCl for 30 min, and then ACh or other agonists were added for 30 min. When the effects of antagonists on the basal phosphoinositide response were to be studied, the antagonist was added at different times up to 48 h before the performance of the PI assay. In some instances, the antagonist was washed out (three changes of Krebs bicarbonate solution without Li ϩ over a period of about 15 min) before adding Li ϩ for 30 min to initiate the PI assay. Immunocytochemistry-Expression of receptor protein was assessed 72 h after transfection by incubation of fixed, permeabilized cells with a 1:100 dilution of an immunoaffinity-purified antiserum raised against the C-terminal 13 amino acids of the M 1 mAChR sequence (13). This was followed by incubation with a 1:5000 dilution of an alkaline phosphatase-labeled second antibody and visualization as described (13) . Data Analysis-Binding curves were analyzed (10, 12, 13) using SigmaPlot (SPSS Software Inc.). Ligand saturation curves were fitted to a one-site model of binding to yield an affinity constant, K Bin , and a total concentration of binding sites, R T . Competition curves were fitted to the Hill equation, or to one-site or two-site models of binding. Binding constants were corrected for the Cheng-Prusoff shift, as necessary (13) . Unless otherwise stated, the agonist K Bin is taken to be the reciprocal of the corrected IC 50 value. PI dose-response curves were fitted to a fourparameter logistic function, yielding a basal activity (PI bas ), a maximum response (PI max ), an EC 50 value, and a slope factor. The slopes of the PI dose-response curves were, on average, not significantly different from 1 In performing these calculations, we have used the value of 20 for R T for the wild-type receptor estimated in a previous study in which the effect of an irreversible blocking agent on the ACh dose-response curve was studied (13) . Values of R T for the different mutants were calculated from the expression of [ 3 H]NMS binding sites. For the L116A mutant, the calculated R T value of 0.4 is consistent with the experimentally determined E max of 40% of wild type (legend to Fig. 3) .
Materials-(Ϫ)-N-[
The agonist signaling efficacy parameter is
, where K G is the apparent affinity constant of the G protein for the ensemble of agonist-receptor complexes. K G was computed to reproduce the pEC 50 of the PI dose-response curve.
For values of R T Ͼ 1, the efficacy parameter, K G , was calculated as follows.
These equations are extensions of those derived by Whaley et al. (18) . Other details are given by Hulme and Lu (16) . When R T was Ͻ1, the efficacy was calculated from a fit of the ternary complex model to the dose-response data, as described previously (13) .
RESULTS

H-Labeled Antagonist Binding and Receptor
ExpressionSeveral Ala substitution mutations in the N-terminal half of TMD 3 strongly reduced the affinity of the quaternary antagonist NMS (Fig. 1a ). D105A and Y106A gave 100-fold reductions, measured by direct radioligand saturation or by competition binding assays (10). 10-Fold reductions followed mutations of Trp 101 , Leu 102 , Asn 110 , and Val 113 . Large decreases were also seen in the affinity of the tertiary antagonist QNB (legend to Fig. 1 ), 6000-fold for D105A (measured by competition with [ 3 H]NMS), and 31-fold for Y106A. In contrast, mutations in the C-terminal part of TMD 3 had little effect on NMS affinity. The largest change was a 2-fold reduction, from I119A ( Fig. 1a) .
Ala substitutions in the C-terminal part of the domain had the largest effects on the expression of [ 3 H]NMS binding sites. The L116A mutant was expressed at 2% of the wild-type level.
Mutations of Val
113 , Asn 115 , and Leu 117 also caused greater than 3-fold reductions (Fig. 1b) . In the N-terminal region, only the mutation of Asp 105 decreased receptor expression, to 10% of the wild-type level. Unusually, mutation of Asn 110 somewhat enhanced receptor expression.
Alterations in the expression of the receptor protein were also visualized by immunocytochemical staining of transfected cells using an antibody directed against the C terminus of the receptor (Fig. 2) . As noted previously, the apparent variation in staining intensity was less than might be expected from the variation in expression of binding sites, suggesting that, particularly in the case of poorly expressing mutants such as D105A (Fig. 2e) , part of the receptor protein was misfolded or was inappropriately localized (13) .
Acetylcholine Binding-Acetylcholine binding was assayed by inhibition of the binding of Mutations that diminished NMS affinity caused reductions in the affinity of ACh (Fig. 3a) . Mutation of Ser 109 , which was without effect on NMS binding, gave a 10-fold reduction in the affinity of ACh.
Three mutations located between the center and the C terminus of TMD 3 increased the affinity of ACh by between 4-and 30-fold. They were V113A, L116A, and S120A.
ACh-stimulated Phosphoinositide Response-In COS-7 cells transfected with the wild-type M 1 mAChR, ACh elicits a robust phosphoinositide response, with an EC 50 of 70 nM and a maximum stimulation of 3 times the basal activity (13) . Qualitatively, the effects of the Ala substitution mutations on the PI response were parallel to their effects on ACh binding. Mutations that decreased ACh affinity decreased the K Act (defined as 1/EC 50 ), while mutations that increased ACh affinity increased the K Act (Fig. 3b) . However, S112A decreased ACh potency without affecting its affinity.
The quantitative effects of the D105A, Y106A, and I119A mutations on ACh potency in the PI response were much greater than their effects on ACh binding. In particular, the D105A mutant completely failed to give a PI response to ACh stimulation, and ACh potency was decreased by more than 1000-fold by both the Y106A and I119A mutations. The basal PI activities of most of the mutant receptors were between 92% (I119A) and 112% of the wild-type basal, but that of the S120A mutant was significantly raised (122 Ϯ 6%; p Ͻ 0.01; Basal ϭ 0.07).
Computation of Agonist Signaling Efficacy-Receptor-transducer models (19) , such as the ternary complex model (17) , can be used to quantitate the effects of mutations on signaling efficacy. Provided that signal generation is directly proportional to the sum of the concentrations of the RG binary and ARG ternary complexes, there exists a quantitative relationship between the maximum response, E max (as a fraction of the maximum obtainable signal); the K Act ; the basal activity parameter, Basal; and the agonist binding constant, K Bin (parameter definitions are given under "Experimental Procedures"). When the ratio of receptor concentration to accessible G protein concentration is greater than 1, the relationship is as follows.
For the present set of mutants, as well as R123A, R123K (12) , and D105E (10), this relationship is reasonably well obeyed (Fig. 4a) . In only one case, N115A, was the deviation of the measured from the predicted E max greater than 20% of the total signal, suggesting a reduction in the signaling activity of the ternary complex in this case.
A measure of agonist signaling efficacy, adjusted for differences in receptor expression level, is provided by the affinity of the G protein for the ensemble of agonist-receptor complexes, , and the ratio of the maximum ACh-stimulated signal to the basal signal was 3.3 Ϯ 0.1. The D105A mutant was inactive in the PI assay. The basal activities of the mutant receptors were between 92 and 112% of the wild-type basal, except for S120A, which was 122 Ϯ 6% of wild-type basal. The E max values were 100% of the wild-type, except for D105A (0%), Y106A (70 Ϯ 4%), S112A (81 Ϯ 7%), N115A (67 Ϯ 5%), L116A (40 Ϯ 2%), and I119A (31 Ϯ 7%). GTP Shifts-The effects of the nonhydrolyzable GTP analogue GTP␥S (10 Ϫ5 M) were investigated on the mutants that showed enhanced ACh affinity and efficacy. Binding studies were performed in the presence of 2 mM Mn 2ϩ ions to promote the stability of the agonist-receptor G protein complex (12) . Mn 2ϩ increased the affinity of ACh for the wild-type receptor by 1.5-fold relative to the standard Mg 2ϩ -containing buffer, but no significant GTP␥S shift resulted. The V113A, and L116A mutants also showed no GTP shift. Mn 2ϩ enhanced the affinity of ACh for the S120A mutant by 3-fold; in this case, the binding data could be described by a two-site model of binding (pK dL ϭ 5.74 Ϯ 0.01 (60% of total sites); pK dH ϭ 7.33 Ϯ 0.06 (40% of total sites)). GTP␥S gave a significant decrease in the ACh affinity for this mutant. Analysis showed a 3.5-fold decrease in the high affinity binding constant (pK dH ϭ 6.79 Ϯ 0.11; p Ͻ 0.05) without an effect on the low affinity binding constant. The partial nature of this effect indicates that only a fraction of the high affinity sites were affected.
Pilocarpine Activation-The mutants that showed increased ACh affinity and efficacy were probed with the partial agonist pilocarpine. Pilocarpine gave 78% of the maximum PI response elicited by ACh at the wild-type receptor (Fig. 5) . With respect to the wild-type receptor, V113A and L116A gave approximately 10-fold increases in affinity for pilocarpine, while S120A gave less than a 2-fold enhancement (Fig. 5) . The potencies of pilocarpine in the PI response were increased by all three mutations. At the V113A and S120A mutants, pilocarpine became a full agonist. At the L116A mutant, its maximum effect was maintained with respect to that of ACh, despite the very low expression of the mutant receptor.
Calculation of the efficacy of pilocarpine gave a value equal to 1.4% of the efficacy of ACh at the wild-type receptor. This was increased to 5% (3.6-fold) for the S120A and V113A mutants and to 30% (21-fold) for the L116A mutant.
Tests for Constitutive Activity-The mutants that showed enhanced ACh and pilocarpine efficacies were examined for inverse agonist effects. Preincubation of transfected cells with NMS for 24 -48 h before the addition of LiCl and the isolation of phosphoinositides reduced the basal activity of the S120A mutant (Basal ϭ 7% of the maximum PI signal) to the wildtype basal level with an IC 50 of 10 Ϫ8 M (Fig. 6a) . There was no detectable effect of NMS on the basal activity of the wild-type receptor, but in some experiments a reduction of about 3% in the V113A Basal parameter was seen (not shown).
Prolonged incubations of cells transfected with the L116A mutant with NMS (Fig. 6a) or atropine increased the basal PI signal. To see whether this effect might be partly mediated by an ability to stabilize, and so up-regulate, the receptor, we examined the effect of atropine on the level of expression of the L116A mutant by immunocytochemistry and by [ A 48-h incubation of the cells with atropine increased the accumulation of the L116A protein (Fig. 2d) but not the wildtype receptor (Fig. 2c ). Measurement of [ 3 H]NMS saturation curves after atropine pretreatment of the cells showed no effect on the wild-type receptor, but the expression of the L116A mutant was increased by up to 50-fold, close to the wild-type level, without changing the NMS affinity (Fig. 6b) . E max values are expressed relative to that of the wild-type receptor. b, log of the efficacy of ACh at the mutant relative to the efficacy at the wild-type receptor. The method of calculation is described under "Experimental Procedures." The values of the efficacy parameter calculated for the wild-type receptor, L116A, and S120A were 6.4, 13.8, and 8.8, respectively. The D105A mutant had zero efficacy. pine (10 Ϫ4 M) also doubled the expression of the D105A mutant (data not shown).
Atropine pretreatment of the transfected cells, followed by washout, before measurement of the PI response increased the basal activity of the L116A mutant to a level equivalent to 70 -120% of the maximum signal obtained in cells transfected with the wild-type receptor. The enhanced basal activity was partially inhibited by the addition of atropine, with an IC 50 of 10 Ϫ8 M (Fig. 6c) . The PI signal was stimulated by 40% by the addition of carbachol (Fig. 6c) or ACh (not shown). The Basal parameter was equivalent to 70% of the maximum signal in these cells. In contrast, pretreatment with atropine had no effect on the PI response of the wild-type receptor.
DISCUSSION
One category of residues is those whose mutation had minimal effect, defined as less than a 3-fold change in the level of receptor expression, in NMS and ACh affinities and less than a 6-fold change in ACh functional potency. Five of these (Leu 100 , Ala 103 , Leu 104 , Val 107 , and Ala 108 ) occur in the N-terminal half of TMD 3, and three (Met 114 , Leu 118 , and Phe 121 ) occur in the C-terminal half. In a helical wheel plot, they are clustered in one sector (Fig. 7a) , strongly supporting an ␣-helical conformation for TMD 3. Cys substitution mutants of the equivalent positions in the D 2 receptor failed to react with a polar sulfhydryl reagent (6) . In both receptor types, these residues probably face toward the lipid bilayer. A helical net representation (Fig.  7b) shows that the sector of TMD 3 in which mutations can be made without major effect narrows toward the cytoplasmic end of the helix, in agreement with models based on the structure of rhodopsin, which suggest that this part of the helix is mostly surrounded by the other TMDs (1).
The residues whose mutation lowered receptor expression levels have the opposite distribution. They are concentrated in the C-terminal half of TMD3 (Fig. 7b) and are spread over 220°o f arc. We have argued that the side chains of such residues make intramolecular contacts that contribute to the stability of the transmembrane structure of the ground state of the receptor (13) . Their removal reduces the free energy of the folded state with respect to inactive intermediates on the folding pathway. Besides Asp 122 and Tyr 124 (13), we have now found a third position, Leu 116 , at which a side chain deletion strongly reduced the level of expression. Three other mutations in the C-terminal part of the helix also had significant effects. Only one such sensitive residue occurs in the N-terminal half of the helix. Interestingly, it is the binding site aspartate itself. The distribution of these mutants suggests that the side chains of residues in the C-terminal half of TMD 3 make more frequent intramolecular contacts than those in the N-terminal half. The free energy difference between the folded and unfolded states was restored by incubation of the expressing cells with a high affinity antagonist. This counteracted the effect of the L116A mutation on expression and doubled the expression of the D105A mutant.
At three of the six positions in the C-terminal half of the domain (Val 113 , Leu 116 , and, as reported in Ref. 13, Asp 122 ), mutations that decreased expression levels increased ACh affinity; in two cases (Val 113 and Leu 116 ), signaling efficacy and/or basal activity was also increased. Mutations of acidic residues homologous to Asp 122 in rhodopsin (20, 21) , the ␣1 receptor (22) , and the ␤2 receptor (23) increased agonist affinity, enhanced efficacy of a partial agonist, and an increased GTP shift (24, 25) . Together, Val 113 , Leu 116 , and Ser 120 form a compact patch of residues located on the inward facing surface of the cytoplasmic half of TMD 3 (Fig.  7b) .
In the extended ternary complex model of agonist-receptor-G protein interaction, a conformational equilibrium is postulated to exist between preexisting ground and active states of the receptor, governed by an isomerization constant, K (24) . Agonists bind to the ground state conformation with low affinity, K a , but to the activated state with a higher affinity, ␣⅐K a . In the simplest case, the G-protein binds selectively to the activated conformation. The extended ternary complex model offers three routes to mutational effects on efficacy: a change in the isomerization constant, K; a change in the agonist cooperativity, ␣; or a change in the affinity of the G protein for the activated receptor, K G.
A selective increase in K provides the most economical explanation for the simultaneously increased basal activity, agonist affinity, and signaling efficacy of the group of constitutively active mutants (24), although it is not possible entirely to exclude an increase in K G , combined with a simultaneous increase in K a or in the cooperativity factor ␣. A priori, an increase in K G seems unlikely to result from a side chain deletion.
Detailed calculations based on the assumption of a changed isomerization constant (described in Ref. 16 ) have suggested a value of about 2 ϫ 10 Ϫ4 for K for the wild-type M 1 receptor and increases of about 2-and 40-fold in this parameter for the S120A and L116A mutants. Particularly in the case of L116A, this may reflect a selective destabilization of the ground state of the receptor, because the expression of the mutant was decreased by approximately the same ratio. These changes are enough to account for the observed increases in the ACh binding affinity, as well as in the ACh signaling efficacy, without an increase in the ground state binding constant, K a (16) . However, in the case of the L116A mutant, K a for pilocarpine may be increased. The pharmacology of this mutant would repay further investigation, particularly as it retains some signaling activity even in the presence of NMS and atropine (Fig. 6, a and  c) . This may imply a partial uncoupling of the ligand binding site from the G protein binding site.
For V113A, there is a 30% increase in the signaling efficacy of ACh (16) , and a 3-fold increase for pilocarpine. However, the 10-fold increases observed in ACh and pilocarpine binding affinity and a significant decrease in antagonist affinity imply an additional perturbation of the ground state conformation of the receptor by this mutation.
The residues whose mutation decreased the signaling efficacy of ACh form a strip extending the full length of TMD 3 (Fig. 7b) . In the outer, N-terminal, part of the helix, they lie on the opposite face to the sector of null residues. In the inner, C-terminal, part, they are displaced by one residue (100°of arc) from the group of residues whose mutations enhanced signaling.
The 16 . The dotted arrow denotes decreased catalytic activity of the ternary complex. *, a 10-fold decrease in NMS affinity; **, a 100-fold decrease in NMS affinity. Residues whose mutation increased both ACh affinity and signaling efficacy are colored red. Residues whose mutation decreased signaling efficacy are colored dark blue. Those whose mutation only decreased ACh affinity are colored light blue. Asp 122 (D122) and Tyr 124 (Y124), for which mutations decrease expression levels and in several cases increase ACh affinity, are colored pink; expression levels are for the D122A-d loop and Y124C mutants (13) .
